MetaCap

RenovoRx (RNXT) vs Verrica Pharmaceuticals (VRCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Verrica Pharmaceuticals (VRCA) over the past year, gaining 18.3% versus a loss of 34.9%. Over five years, RNXT leads with a -85.3% price change compared with -97.4% for VRCA. Verrica Pharmaceuticals is the larger company by market cap ($47.1 million vs $45.5 million), about 1.0 times the size, while RenovoRx is growing revenue faster (+2511.6% vs +370.2%).

Verrica Pharmaceuticals converts more of its revenue into profit, with a net margin of -50.3% versus -994.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RNXT+18.34%VRCA-34.92%
+229%+91%-47%
Nov 21, 20251 yearNov 20, 2026
RNXT-85.71%VRCA-97.60%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RNXT versus VRCA key metrics
MetricRNXTVRCA
Share price$0.942$2.74
Market cap$45.45M$47.07M
1-day change-10.29%-5.03%
YTD return+12.14%-67.03%
1-year return+18.34%-34.92%
5-year return-85.26%-97.38%
EPS (TTM)$-0.31$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.12M$35.58M
Revenue growth (YoY)+2511.63%+370.22%
Net income (latest FY)$-11.17M$-17.89M
Gross margin70.88%—
Operating margin-1113.98%-34.25%
Net margin-994.48%-50.27%
52-week high$2.59$9.82
52-week low$0.77$2.73
Distance from 52-week high-63.63%-72.10%
Analyst consensusnonestrong_buy
Avg. price target upside+656.90%+404.74%
Average volume815.75K68.78K
Shares outstanding48.25M17.18M
Employees1776
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNXT has outperformed VRCA by 53.3 percentage points over the past year.
  • Verrica Pharmaceuticals is more profitable, keeping -50.3 cents of every revenue dollar as net income versus -994.5 cents for RenovoRx.
  • RenovoRx grew revenue faster in its latest fiscal year (+2511.63% vs +370.22%).

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Verrica Pharmaceuticals

VRCA stock →

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

RNXT vs VRCA FAQ

Which is bigger, RenovoRx or Verrica Pharmaceuticals?

Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $47.07M compared with $45.45M for RenovoRx (RNXT).

Which stock has performed better over the past year, RNXT or VRCA?

RNXT returned +18.34% over the past 12 months, compared with -34.92% for VRCA (price return, excluding dividends). Past performance does not predict future results.

Are RenovoRx and Verrica Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons